Our Pricing

Essential Promethazine BNF Safety Guidelines

Understanding promethazine BNF safety guidelines UK is essential for safe use of this widely prescribed antihistamine. Promethazine hydrochloride, available as Phenergan tablets and elixir, requires careful attention to dosing, contraindications, and drug interactions as outlined in the British National Formulary. At Cured Pharmacy, our UK-registered clinical team ensures every prescription aligns with current BNF guidance before dispensing.

Promethazine BNF Classification and Mechanism

The BNF classifies promethazine as a first-generation sedating antihistamine with additional antimuscarinic and antiemetic properties [1]. Unlike newer non-sedating antihistamines, promethazine crosses the blood-brain barrier readily, producing central nervous system depression that makes it effective for short-term insomnia and motion sickness.

Promethazine competitively blocks histamine H1 receptors, preventing histamine-mediated vasodilation, increased vascular permeability, and pruritus [1]. The antimuscarinic effects reduce secretions and vestibular stimulation, whilst dopamine D2 receptor antagonism in the chemoreceptor trigger zone provides antiemetic action. Clinical studies demonstrate onset within 20 minutes of oral administration, with peak plasma concentrations at 2-3 hours and duration of action up to 12 hours [2].

BNF-Recommended Dosing for Adults and Children

The BNF provides specific age-stratified dosing for promethazine across its licensed indications. For allergic conditions in adults, the standard dose is 25mg at night, or 10-20mg two to three times daily if daytime sedation is acceptable [1]. Short-term insomnia treatment requires 25mg taken 20 minutes before bedtime, limited to a maximum of seven consecutive nights to prevent tolerance development.

Paediatric dosing requires particular care. The BNF contraindicates promethazine in children under two years due to fatal respiratory depression risk [1]. For children aged 2-5 years, doses range from 5-15mg daily depending on indication, whilst those aged 5-10 years may receive 10-25mg daily. Motion sickness prevention in children over 5 years involves 25mg the night before travel, with a second dose 1-2 hours before departure if needed.

Elderly Patient Considerations

The BNF advises reduced initial doses in elderly patients, who demonstrate increased sensitivity to anticholinergic effects including confusion, urinary retention, and falls [1]. Our superintendent pharmacist Tarun Kumar recommends starting with 10mg doses in patients over 65, with careful titration based on response and tolerability. Cognitive assessment should precede promethazine initiation in this population.

Absolute and Relative Contraindications

The BNF lists several absolute contraindications for promethazine. These include hypersensitivity to phenothiazines, children under two years, comatose states, and concurrent monoamine oxidase inhibitor therapy [1]. Promethazine must not be used within 14 days of MAOI discontinuation due to risk of severe hypertensive crisis and serotonin syndrome.

Relative contraindications requiring prescriber assessment include severe coronary artery disease, angle-closure glaucoma, prostatic hypertrophy, pyloroduodenal obstruction, epilepsy, and hepatic impairment [1][3]. Patients with Reye's syndrome history should avoid promethazine, as phenothiazines may mask early vomiting symptoms. The MHRA has issued specific warnings about respiratory depression risk in children with respiratory conditions including asthma and sleep apnoea.

Pregnancy and Breastfeeding Guidance

The BNF advises avoiding promethazine during pregnancy unless essential, particularly in the third trimester where neonatal irritability and tremor have been reported [1]. Limited human data suggest no major teratogenic risk, but animal studies show potential adverse effects. During breastfeeding, promethazine passes into breast milk in small amounts and may cause drowsiness or irritability in nursing infants. Short-term use of lower doses may be acceptable with close infant monitoring, subject to prescriber approval.

Clinically Significant Drug Interactions

The BNF documents numerous pharmacodynamic interactions with promethazine that require clinical management [1]. Concurrent use with other CNS depressants including alcohol, benzodiazepines, opioids, and Z-drugs produces additive sedation and respiratory depression. Patients must be counselled to avoid alcohol completely and to inform prescribers of all sedating medications.

Anticholinergic burden increases substantially when promethazine is combined with tricyclic antidepressants, antimuscarinics for urinary incontinence, or antipsychotics [3]. This combination elevates risk of cognitive impairment, constipation, dry mouth, and urinary retention. The BNF also warns about QT interval prolongation when promethazine is used alongside macrolide antibiotics, antiarrhythmics, or other QT-prolonging agents, necessitating ECG monitoring in at-risk patients.

Common and Serious Adverse Effects

The BNF categorises promethazine adverse effects by frequency and severity. Very common effects include drowsiness, sedation, and dry mouth, affecting more than 10% of users [1]. Common anticholinergic effects (1-10% frequency) encompass blurred vision, urinary retention, constipation, and dizziness. These effects typically diminish with continued use but may necessitate dose reduction or discontinuation.

Serious adverse reactions, though uncommon, require immediate medical attention. Extrapyramidal symptoms including acute dystonia, akathisia, and tardive dyskinesia have been reported, particularly with prolonged use or higher doses [1][2]. Neuroleptic malignant syndrome, characterised by hyperthermia, muscle rigidity, and autonomic instability, represents a rare but life-threatening emergency. Blood dyscrasias including leucopenia and agranulocytosis occur rarely but mandate promethazine cessation if unexplained infection or fever develops.

Photosensitivity and Skin Reactions

The BNF notes that phenothiazines including promethazine can cause photosensitivity reactions, with patients developing exaggerated sunburn after minimal UV exposure [1]. Contact dermatitis may occur with topical formulations. Patients should be advised to use high-factor sunscreen and protective clothing during treatment, particularly during summer months or in sunny climates.

Safe Prescribing and Monitoring Requirements

BNF guidance emphasises that promethazine prescriptions should specify the shortest effective duration, typically not exceeding 7-10 days for insomnia or acute allergic conditions [1]. Longer-term use risks tolerance development, rebound insomnia upon cessation, and accumulation of anticholinergic burden. Our UK-registered prescribers at Cured Pharmacy conduct thorough medical history assessments to identify contraindications before approving promethazine treatment.

Patients requiring promethazine should receive comprehensive counselling about drowsiness effects on driving and operating machinery. The DVLA advises that patients must not drive if impaired by medication, with promethazine commonly causing next-day sedation [3]. Regular review is essential for patients on concurrent medications, elderly individuals, and those with hepatic or renal impairment. All promethazine products at Cured Pharmacy, including Phenergan 25mg Tablets and Phenergan Elixir, require clinical assessment by a UK prescriber to ensure BNF-compliant prescribing.

Storage and Administration Guidance

The BNF specifies that promethazine tablets and elixir should be stored below 25°C, protected from light, and kept out of reach of children [1]. Tablets should be swallowed whole with water, whilst the elixir requires accurate measurement using the provided dosing device. Patients should be advised never to share promethazine with others, even if symptoms appear similar, as individual contraindications and drug interactions vary considerably.

Scientific References

1. Joint Formulary Committee. (2024). British National Formulary (BNF) 87. London: BMJ Group and Pharmaceutical Press. https://bnf.nice.org.uk/drugs/promethazine-hydrochloride/
2. Simons, F. E. R., & Simons, K. J. (2011). Histamine and H1-antihistamines: celebrating a century of progress. Journal of Allergy and Clinical Immunology, 128(6), 1139-1150. https://doi.org/10.1016/j.jaci.2011.09.005
3. Medicines and Healthcare products Regulatory Agency. (2019). Promethazine for allergy: new advice on use in children. Drug Safety Update, 12(9), 3-4. https://www.gov.uk/drug-safety-update/promethazine-for-allergy-new-advice-on-use-in-children

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.